6 known cases. View patent page →
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Jazz sued Teva over Teva's ANDA for generic Xywav; the complaint lists the '426 patent among the patents-in-suit. Teva filed invalidity contentions and counterclaims; the case was consolidated with the Lupin actions on Dec. 15, 2023, and remains ongoing with no final judgment on '426 found.
Jazz sued Alkem in a Xyrem-related ANDA action; the complaint asserted the '426 patent plus other patents. The case was voluntarily dismissed, with a Rule 41(a)(1)(A)(i) order signed Oct. 5, 2023, and the case terminated.
Jazz sued Tris Pharma over Tris's January 2026 Section 505(b)(2) NDA for generic Xyrem/Xywav; this docket lists the '426 patent among asserted patents and also lists '400, '181, '494, '446, '306, and '302. The matter appears active.
Jazz sued Amneal over sodium oxybate ANDA No. 203631; Amneal's counterclaims expressly asserted that each claim of the '426 patent is invalid, confirming '426 was in suit. The outcome was not confirmed in the retrieved sources; the broader Jazz/Amneal Xyrem family was ultimately settled, but the '426 disposition specifically is unverified.
Antitrust class action, not patent infringement, in the Xyrem/Xywav pay-for-delay litigation. The complaint lists the '426 patent among the patents at issue in Jazz's Orange Book/patent-settlement conduct.